- Krystal Biotech, Inc. (NASDAQ:KRYS) reported earnings per share of $1.70, beating the estimated $1.62, and revenue of $107.1 million, surpassing the $105.1 million estimate.
- The company’s successful commercialization of VYJUVEK contributed to a total revenue of $730.3 million since its U.S. launch.
- Krystal Biotech’s strong liquidity position is highlighted by $955.9 million in cash and investments, with a current ratio of 10.14 and a low debt-to-equity ratio of 0.0084.
Krystal Biotech, Inc. (NASDAQ: KRYS) is a biotechnology company that focuses on developing genetic medicines for diseases with unmet medical needs. On February 17, 2026, KRYS reported earnings per share of $1.70, surpassing the estimated $1.62. The company also reported revenue of approximately $107.1 million, exceeding the estimated $105.1 million.
The reported revenue of $107.1 million in the fourth quarter came from VYJUVEK, contributing to a total of $730.3 million since its U.S. launch. This strong performance highlights the company’s successful commercialization efforts. Krystal Biotech’s focus on genetic medicines is further supported by the FDA’s RMAT designation for KB707 and Fast Track Designation for KB111, indicating promising developments in their pipeline.
Krystal Biotech ended the quarter with a robust balance sheet, holding $955.9 million in cash and investments. This strong liquidity position, with a current ratio of 10.14, suggests the company can easily cover its short-term liabilities. The low debt-to-equity ratio of 0.0084 indicates minimal reliance on debt, providing financial stability.
The company’s valuation metrics, such as a P/E ratio of 40.22 and a price-to-sales ratio of 21.47, reflect investor confidence in its growth potential. The enterprise value to sales ratio of 20.44 and enterprise value to operating cash flow ratio of 43.30 highlight the market’s positive outlook on Krystal Biotech’s future performance. With an earnings yield of 2.49%, the company offers a return on investment based on its earnings.
Krish S. Krishnan, Chairman and CEO, emphasized the company’s mission to support patients with dystrophic epidermolysis bullosa globally. Krystal Biotech aims to launch multiple products and treat over 10,000 patients with rare diseases by 2030. The recent readout on cystic fibrosis underscores the versatility of their approach, positioning the company for continued growth and impact in the biotechnology sector.
